Retrospective evaluation of planning margins for patients undergoing radical radiation therapy treatment for bladder cancer using volumetric modulated arc therapy and cone beam computed tomography.


Journal

Journal of medical radiation sciences
ISSN: 2051-3909
Titre abrégé: J Med Radiat Sci
Pays: United States
ID NLM: 101620352

Informations de publication

Date de publication:
Dec 2021
Historique:
revised: 20 06 2021
received: 22 07 2020
accepted: 09 07 2021
pubmed: 22 7 2021
medline: 15 12 2021
entrez: 21 7 2021
Statut: ppublish

Résumé

Current contouring guidelines for curative radiation therapy for muscle-invasive bladder cancer (MIBC) recommend margins of 1.5-2.0 cm, applied to the clinical target volume (CTV). This study assessed whether the use of volumetric modulated arc therapy (VMAT), cone beam computed tomography (CBCT) and strict bladder preparation allowed for a reduced planning target volume (PTV) expansion, resulting in lower doses to surrounding organs at risk (OARs). Daily CBCT images for 12 patients (382 scans total) were retrospectively reviewed against four potential PTV margins created on and exported with the reference CT scan. To form the PTVs, three isotropic expansions of 0.5, 1.0 and 1.5 cm were applied to the CTV, as well as an anisotropic expansion of 1.5 cm superiorly and 1.0 cm in all other dimensions. Following treatment completion, the CBCTs were visually assessed to determine the margins encapsulating the bladder. For retrospective planning purposes, the 1.0-cm and anisotropic margins were compared with the previously recommended margins to determine differences in OAR doses. The 0.5-, 1.0- and 1.5-cm isotropic margins (IM) and the anisotropic margin (ANIM) covered the CTV in 46.1, 96.8, 100 and 100% of CBCTs retrospectively. Doses to OARs were significantly lower for the reduced margin plans for the small bowel, rectum and sigmoid. Bladder planning target volumes may be safely reduced. We endorse a PTV margin of 1.0cm anteriorly, posteriorly and inferiorly with 1.0-1.5 cm superiorly for radical whole bladder cases using strict bladder preparation, VMAT and pretreatment CBCTs.

Identifiants

pubmed: 34288566
doi: 10.1002/jmrs.532
pmc: PMC8656189
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

371-378

Informations de copyright

© 2021 The Authors. Journal of Medical Radiation Sciences published by John Wiley & Sons Australia, Ltd on behalf of Australian Society of Medical Imaging and Radiation Therapy and New Zealand Institute of Medical Radiation Technology.

Références

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):436-44
pubmed: 15145160
Clin Oncol (R Coll Radiol). 2012 Dec;24(10):673-81
pubmed: 22858439
J Nutr Health Aging. 2009 Feb;13(2):150-7
pubmed: 19214345
Mech Ageing Dev. 2014 Mar-Apr;136-137:50-8
pubmed: 24333321
Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):664-71
pubmed: 19473781
Pract Radiat Oncol. 2014 Mar-Apr;4(2):108-115
pubmed: 24890351
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1225-31
pubmed: 23182394
Neurourol Urodyn. 2008;27(8):772-4
pubmed: 18551571
Acta Oncol. 2014 Aug;53(8):997-1004
pubmed: 24957559
J Med Radiat Sci. 2016 Sep;63(3):179-85
pubmed: 27648282
Pract Radiat Oncol. 2019 Jan;9(1):24-28
pubmed: 30096379
Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):892-7
pubmed: 17011462
Am J Clin Oncol. 2018 Feb;41(2):107-114
pubmed: 26535994
Cureus. 2017 Sep 1;9(9):e1638
pubmed: 29119069
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1174-8
pubmed: 16376494
Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1045-53
pubmed: 19540057
Radiother Oncol. 2003 Dec;69(3):291-304
pubmed: 14644489
Clin Oncol (R Coll Radiol). 2014 Aug;26(8):497-505
pubmed: 24726459
Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):261-9
pubmed: 23958147
Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):77-82
pubmed: 23332382
Radiat Oncol. 2015 Sep 25;10:205
pubmed: 26407726

Auteurs

Kathleene Dower (K)

Northern NSW Cancer Institute, Lismore, New South Wales, Australia.

Andriana Ford (A)

Northern NSW Cancer Institute, Lismore, New South Wales, Australia.

Michael Sandford (M)

Mid North Coast Cancer Institute Coffs Harbour, Coffs Harbour, New South Wales, Australia.

Andrew Doherty (A)

Mid North Coast Cancer Institute Coffs Harbour, Coffs Harbour, New South Wales, Australia.

Stuart Greenham (S)

Mid North Coast Cancer Institute Coffs Harbour, Coffs Harbour, New South Wales, Australia.

Luke Kerin (L)

Mid North Coast Cancer Institute Port Macquarie, Port Macquarie, New South Wales, Australia.

Patrick Dwyer (P)

Northern NSW Cancer Institute, Lismore, New South Wales, Australia.

Carmen Hansen (C)

Mid North Coast Cancer Institute Port Macquarie, Port Macquarie, New South Wales, Australia.

Justin Westhuyzen (J)

Mid North Coast Cancer Institute Coffs Harbour, Coffs Harbour, New South Wales, Australia.

Thomas Shakespeare (T)

Mid North Coast Cancer Institute Coffs Harbour, Coffs Harbour, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH